Can Provenge Cure Prostate Cancer?
Written by Jack Leeroy   
April 21, 2007
Chicago, IL. -- Apr 21, 2007 -- /prbuzz/ -- PROVENGE is an investigational product that may represent the first in a new class of active cellular immunotherapies that are uniquely designed to stimulate a patient's own immune system. PROVENGE is in late-stage clinical development for the treatment of patients with advanced prostate cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

The FDA has to give their opinion on whether they will or will not approve the drug provenge on May 15th. If the FDA issue an approval letter, then the company Dendreon would have to provide additional data to the FDA on 2010.

WARNING: Investing in a drug that the FDA has not approve is Gambling. Gambling can cost you all of your money.

Investing in a drug Provenge that the FDA has not approve is Gambling,
and Gambling can cost you all of your money.

What's the best thing to do?

I think the best thing to do is to take profit, and wait until May
15th. That's when the FDA will issue a conformation whether they will
or will not approve the drug Provenge.

If you buy the stock "DNDN" at this point betting on that the FDA will
approve the drug is Gambling. Gambling will cost you all of your
money, and gambling can break up your mariage.

If you are an addicted gambler please contact the Gambler Anonymous
information below.

Gam-Anon® International

Service Office, Inc.
PO Box 157
Whitestone, NY 11357
718-352-1671 phone
718-746-2571 fax

Source: http://www.1pennystock.com/dendreon/provenge.html

1pennyStock.com offers free stock research. 1pennyStock.com does not offer stock recommendations. You should always consult your broker before you buy or sell any securities.
About the Press Release
PROVENGE is an investigational product that may represent the first in a new class of active cellular immunotherapies that are uniquely designed to stimulate a patient's own immune system.


 
< Prev   Next >